恒生创新药ETF（159316）标的指数盘初走强，121款创新药进入商保初审目录

Group 1 - The Hong Kong stock market for innovative drugs is experiencing a rebound, with stocks like Innovent Biologics, Kintor Pharmaceutical, and BeiGene showing strength, as the Hang Seng Innovative Drug Index rose by 1.1% as of 9:40 AM [1] - The Hang Seng Innovative Drug ETF (159316) saw a trading volume exceeding 50 million yuan, marking its highest scale at 1.16 billion yuan since inception, following four consecutive trading days of capital inflow [1] - The National Healthcare Security Administration announced the preliminary review of 121 drug generic names for the commercial insurance innovative drug directory, with monoclonal antibody injections being the main focus, particularly PD-(L)1 monoclonal antibodies, involving companies like Lepu Biopharma, Hengrui Medicine, and others [1] Group 2 - CITIC Securities expressed a long-term positive outlook on the innovative drug sector, emphasizing the importance of innovation-driven strategies, internationalization, and reforms in outpatient marketing models [1] - The new compilation scheme for the Hang Seng Innovative Drug Index has officially taken effect, excluding CXO companies and focusing solely on innovative drug firms, achieving a "purity" of 100% [1] - Backtesting indicates that the adjusted index has higher annualized returns and Sharpe ratios since its release on July 10, 2023, with the Hang Seng Innovative Drug ETF (159316) being the only product tracking this index, aiding investors in accurately grasping industry trends [1]